{"id":11242,"date":"2019-10-21T00:00:00","date_gmt":"2019-10-21T05:00:00","guid":{"rendered":"https:\/\/myeloma.ca\/1970\/01\/01\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/"},"modified":"2025-08-19T08:28:20","modified_gmt":"2025-08-19T13:28:20","slug":"nouvelle-recommandation-de-remboursement-pour-pomalyst","status":"publish","type":"post","link":"https:\/\/myeloma.ca\/fr\/2019\/10\/21\/nouvelle-recommandation-de-remboursement-pour-pomalyst\/","title":{"rendered":"NOUVELLE RECOMMANDATION DE REMBOURSEMENT POUR POMALYST"},"content":{"rendered":"<p>L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la l\u00e9nalidomine.<\/p>\n<p><a href=\"https:\/\/www.cadth.ca\/fr\/pomalidomide-pomalyst-en-association-avec-dexamethasone-et-bortezomib-dans-le-traitement-du-myelome?utm_source=CONS+List&amp;utm_campaign=dcda58cc00-pCODR-08-01-2019-final-recs_COPY_01&amp;utm_medium=email&amp;utm_term=0_f3b3313866-dcda58cc00-263006281\" target=\"_blank\" rel=\"noopener\">Voir les crit\u00e8res de remboursement<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>L\u2019Agence canadienne des m\u00e9dicaments et des technologies de la sant\u00e9 a \u00e9mis une nouvelle recommandation concernant le Pomalyst (pomalidomide). Pomalyst, en association avec dexam\u00e9thasone et bort\u00e9zomib, est maintenant indiqu\u00e9 dans le traitement des patients adultes atteints de my\u00e9lome multiple (MM) r\u00e9cidivant ou r\u00e9fractaire qui ont d\u00e9j\u00e0 re\u00e7u au moins une forme de traitement comprenant la [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,50,58,52],"tags":[],"class_list":["post-11242","post","type-post","status-publish","format-standard","hentry","category-actualites-et-evenement","category-news-events","category-nouvelles-de-myelome-canada","category-whats-new-at-myeloma-canada"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11242","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/comments?post=11242"}],"version-history":[{"count":1,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11242\/revisions"}],"predecessor-version":[{"id":31323,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/posts\/11242\/revisions\/31323"}],"wp:attachment":[{"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/media?parent=11242"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/categories?post=11242"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/myeloma.ca\/fr\/wp-json\/wp\/v2\/tags?post=11242"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}